Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


The Nurse Practitioner

January 2013, Volume 38 Number 1 , p 56 - 56



Janssen Pharmaceuticals, Inc. has received approval for an additional indication for tapentadol extended release oral tablets (Nucynta ER).The tablets manage neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.Nucynta ER is a centrally acting synthetic analgesic and is the first and only opioid approved by the FDA for neuropathic pain associated with DPN.The most common adverse reactions associated with the medication in clinical trials are nausea, constipation, vomiting, dizziness, headache, and somnolence.Nucynta ER labeling contains a warning about abuse potential, life-threatening respiratory depression, accidental exposure, and interaction with alcohol. Consult product labeling for important prescribing information and contraindications.Abbott's adalimumab (Humira) is now indicated for the treatment of adult patients with moderate-to-severe ulcerative colitis (UC)

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: